Share

What's New?

As of December 2012

Pipeline Update

Anti-HER3/EGFR MAb (MEHD7945A) was added to the Genentech Pipeline.

Content Updates

Pipeline Molecules: Obinutuzumab (GA101): Content Update

As of August 2012

Clinical Trials

A new interface was developed making it easier to search and find relevant trials.

Content Updates

• Biological Pathways: Angiogenic Signaling: Content Update
• Biological Pathways: HER Signaling: Content Update
• Therapeutic Targets: Content Update
• Therapeutic Targets: EGFL7: Content Update
• Therapeutic Targets: HER1: Content Update
• Therapeutic Targets: VEGF: Content Update
• Pipeline Molecules: Overview: Content Update
• Pipeline Molecules: Anti-EGFL7: Content Update
• Clinical Endpoints: Content Update

As Of: May 2012

Pipeline Molecules Feature

• We've added a brochure that shows the full breath of the Roche/Genentech Oncology Pipeline.

Content Updates

• 
  Therapeutic Targets: Bcl-2: Content Update
• 
  Research Education: Research ADCs: Content Update
• 
  Pipeline Molecules: MetMab: Video Update

Updated Video Narrations

• 
  Biological Pathways: Apoptosis: Updated Video

Conferences

• Conferences have been updated and now you can find them by tumor type and profession.

PubMed Codes

• Pubmed codes have been added to all references on the site, allowing you to quickly locate the source articles on Pubmed.com.

Example Reference

1.

Tabernero J, Cervantes A, Saura C, Roda D, Yan Y, Patel P. Targeting the PI3K-Akt-mTOR pathway with GDC-0068, a novel selective ATP competitive Akt inhibitor. Ann Oncol. 2011;22(suppl 3):abstract IL33. PMID: 17604717

Information About Cancer

• Visit InformationAboutCancer.com to learn about a unique website that brings information, support, and resources about cancer right to your patient’s fingertips.

Clinical Endpoints

• Visit the clinical endpoints section to find clinical trial design, endpoints and more.